Table 2.
Adverse events
| All patients | R-ICE-zanubrutinib (n = 34) | ICE-lenalidomide (n = 30) |
R-ICE-decitabine (n = 9) |
|||||
|---|---|---|---|---|---|---|---|---|
| Adverse events | Any grade |
Grade ≥3a |
Any grade |
Grade ≥3a |
Any grade |
Grade ≥3a |
Any grade |
Grade ≥3a |
| Hematological events | ||||||||
| Neutropenia | 60 (79) | 23 (30) | 27 (79) | 10 (29) | 24 (80) | 9 (30) | 8 (89) | 4 (44) |
| Anemia | 39 (51) | 4 (5) | 16 (47) | 3 (9) | 17 (57) | 0 (0) | 5 (56) | 1 (11) |
| Thrombocytopenia | 52 (68) | 19 (25) | 21 (62) | 8 (24) | 22 (73) | 6 (20) | 8 (89) | 5 (56) |
| Non-hematological events | ||||||||
| Nausea or vomiting | 7 (9) | 0 (0) | 3 (9) | 0 (0) | 2 (7) | 0 (0) | 2 (22) | 0 (0) |
| Alanine aminotransferase increased | 20 (26) | 2 (3) | 9 (27) | 1 (3) | 7 (23) | 1 (3) | 3 (33) | 0 (0) |
| Aspartate aminotransferase increased | 18 (24) | 1 (1) | 8 (24) | 1 (3) | 6 (20) | 0 (0) | 3 (33) | 0 (0) |
| γ-glutamyl transferase increased | 7 (9) | 0 (0) | 4 (12) | 0 (0) | 2 (7) | 0 (0) | 1 (11) | 0 (0) |
| Mucositis oral | 3 (4) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 2 (22) | 0 (0) |
| Infectionb | 7 (9) | 5 (7) | 3 (9) | 3 (9) | 3 (10) | 1 (3) | 1 (11) | 1 (11) |
| Cardiac toxicity | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Neurological toxicity | 4 (5) | 0 (0) | 2 (6) | 0 (0) | 1 (3) | 0 (0) | 1 (11) | 0 (0) |
Data are n (%)
R-ICE rituximab plus ifosfamide, carboplatin, and etoposide
a Grading was performed according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE v5.0). The CTCAE v5.0 grades the AEs based on their severity on a 5-point scale, with Grade≥3 indicating severe life-threatening and death
b Includes catheter-related, lung, skin, upper respiratory tract, and urinary tract infections